19/04/2014 15:40:39 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
04/17/20146:22PMBWFDA Approves Merck’s RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short ...
RAGWITEK is the First and Only FDA Approved Sublingual Allergen Immunotherapy Tablet Indicated for the Treatment of Short Ragweed Pollen Allergies Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed... More...>>
04/15/20148:00AMPRNUSInterim Clinical Study Results, Leadership Appointments, and Earnings Release Schedules - Analyst Notes on Merck, Magellan, A...
Interim Clinical Study Results, Leadership Appointments, and Earnings Release Schedules - Analyst Notes on Merck, Magellan, ABIOMED, CONMED, and Greatbatch Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, April 15, 2014 NEW YORK, April 15, 2014 /PRNewswire/ -- Today... More...>>
04/14/20145:59PMBWFDA Approves Merck’s GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Po...
GRASTEK is the Only FDA Approved Sublingual Allergy Immunotherapy Tablet Indicated for Children as Young as 5 Years of Age Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved GRASTEK® (Timothy Grass Pollen Allergen Extract... More...>>
04/11/20141:00AMBWMerck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-...
Clinical Findings Support Initiation of C-EDGE Phase 3 Program Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172... More...>>
04/10/20149:43AMDJNMerck: Hepatitis C Drug Shows 98% Cure Rate in Mid-Stage Trial -- Update
By Michael Calia Merck & Co. said Thursday that a pair of its hepatitis C virus treatments showed a cure rate of 98% in a mid-stage trial, supporting advancement of the study. The drug maker said it has initiated a Phase 3 trial after analyzing the study results of the 12-week regimen using the oral treatment, which... More...>>
04/10/20149:30AMDJNMerck: Hepatitis C Drug Shows 98% Cure Rate in Trial
Merck & Co. said Thursday that a pair of its hepatitis C virus treatments showed a cure rate of 98% in a mid-stage trial, supporting advancement of the study. The drug maker said it has initiated a Phase 3 trial after analyzing the study results of the 12-week regimen using the treatments, MK-5172 and MK-8742. The... More...>>
04/10/20149:09AMDJNMerck: Hepatitis C Drug Shows 98% Cure Rate in Mid-Stage Trial
By Michael Calia Merck & Co. said Thursday that a pair of its hepatitis C virus treatments showed a cure rate of 98% in a mid-stage trial, supporting advancement of the study. The drug maker said it has initiated a Phase 3 trial after analyzing the study results of the 12-week regimen using the treatments, MK-5172... More...>>
04/10/20141:00AMBWMerck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 & MK-8742, in Treatment-Naïv...
Clinical Findings Support Advancement into Phase 3 Trials Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an... More...>>
04/08/20147:00PMZACKSEPO Upholds Alnylam's McSwiggen Patent - Analyst Blog
The European Patent Office (EPO) has upheld Alnylam Pharmaceuticals, Inc.’s (ALNY) McSwiggen EP 1423406 ('406) patent in oral opposition proceedings in Germany. Alnylam’s shares gained around 3.9% following the news. We note that the McSwiggen patent family has 21 granted or issued patents around the world... More...>>
04/08/20148:00AMPRNUSConference Call Schedules, Clinical Trial Studies, Awards and Accolades, Appointments, and Welfare Initiatives - Analyst Note...
Conference Call Schedules, Clinical Trial Studies, Awards and Accolades, Appointments, and Welfare Initiatives - Analyst Notes on Celgene, Johnson & Johnson, Merck, Sanofi, and UnitedHealth Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, April 8, 2014 NEW YORK, April... More...>>
04/07/201412:34PMPRNUSTechnical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly
Technical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, April 7, 2014 LONDON, April 7, 2014 /PRNewswire/ -- On Friday, April 04, 2014, the NASDAQ Composite... More...>>
04/07/20148:00AMPRNUSNDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson &...
NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, April 7, 2014 NEW YORK, April 7, 2014 /PRNewswire/... More...>>
04/06/201410:30AMBWEarly Findings Exploring the Relationship of PD-L1 Expression & Clinical Outcomes with MK-3475, Merck’s Investigational Ant...
Exploratory Analyses in Advanced Melanoma and NSCLC Presented in Oral Session Dr. Roger Perlmutter to Present at AACR Opening Plenary Session Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of early findings from studies exploring the relationship between tumor PD-L1... More...>>
04/04/20148:00AMBWMerck, Ferring Pharmaceuticals & the World Health Organization Working Together to Prevent Excessive Bleeding in Women after ...
Post-partum Hemorrhage Is Leading Cause of Mothers Dying Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ferring Pharmaceuticals today announced their collaboration with the World Health Organization (WHO) to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding... More...>>
03/31/20142:00PMZACKS3 ETFs to Watch as Obamacare Hits Deadline - ETF News And Commentary
Despite the rocky start and a plethora of technical issues, the Affordable Care Act (often known as Obamacare) saw a surge in enrollment in the final days of its first year program. More than 6 million Americans (as of March 27) have signed up for medical insurance under this healthcare law since October 2013, meeting the... More...>>
03/30/20148:46AMDJNMARKET SNAPSHOT: Play-it-safe Stock Investors May Take Some Risk On Jobs
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- For stock investors, the first quarter was a mild drag as investors played it safe in defensive sectors. Next week's news, highlighted by the March jobs report, promises more fireworks. But for real gains, such as the type that lift benchmarks to new highs... More...>>
03/30/20148:44AMDJNNew Drugs to Lower Cholesterol Show Promise: Studies
By Ron Winslow WASHINGTON--An experimental class of cholesterol-lowering drugs is emerging as the most promising new weapon against cardiovascular disease since the widely used medicines called statins first reached the market more than 25 years ago, medical studies show. In a flurry of studies presented over the weekend... More...>>
03/28/20146:57PMDJNMerck CEO Frazier: Consumer Unit Draws 'Substantial' Interest -Fox News
Merck & Co. (MRK) Chief Executive Kenneth Frazier said the company has received "substantial" interest in the consumer business it's selling, in an interview that will air on Fox News Channel's "Sunday Morning Futures with Maria Bartiromo." Mr. Frazier said he wouldn't comment on the price of specific bids but said... More...>>
03/28/20148:00AMPRNUSPositive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analys...
Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, March 28, 2014 NEW YORK, March... More...>>
03/27/20149:44AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Thursday's session are Citigroup Inc. (C), GameStop Corp. (GME) and Winnebago Industries Inc. (WGO). Accenture PLC (ACN) said its fiscal second-quarter revenue grew as the consulting firm benefited from improvement in its outsourcing business. The company raised... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk140419 15:40